Skip to main content
. 2019 Aug 9;10(11):1867–1870. doi: 10.1039/c9md00233b

Fig. 2. Three non-nucleoside inhibitors against herpes-viruses addressing the viral helicase–primase as a novel target. Pritelivir (company code AIC-316) is end of phase II for HSV-1 and HSV-2; ASP-2151 (Amenamevir) is marketed in Japan for herpes zoster (VZV), the development of BIL S-179 BS was suspended.

Fig. 2